Literature DB >> 14751187

Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.

Michele L Donato1, Charles Levenback, David M Gershenson, Scott McMeekin, Richard E Champlin.   

Abstract

BACKGROUND: We are reporting on a case of platinum-refractory low-grade ovarian cancer responding to treatment with an allogeneic bone marrow transplantation from an unrelated donor. CASE: The 37-year-old patient received a preparative regimen consisting of fludarabine 25 mg/m(2) on days -6, -5, -4, -3 and -2, melphalan 70 mg/m(2) on days -3 and -2, and thymoglobulin 2 mg/kg on days -3, -2 and -1. An unrelated HLA-compatible bone marrow was infused on day 0. Graft-versus-host disease prophylaxis consisted of tacrolimus and methotrexate. The patient demonstrated complete donor chimerism. Serial CT scans of the abdomen and pelvis over the following 15 months showed a slow regression of the malignant lesion.
CONCLUSION: Engraftment of an unrelated donor marrow was achieved in a patient with ovarian cancer and induced a tumor response. This suggests the presence of a graft-versus-tumor effect in ovarian cancer. Further study is underway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751187     DOI: 10.1016/j.ygyno.2003.09.004

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.

Authors:  Rudi Henriksen; Flemming Brandt Sørensen; Torben Falck Ørntoft; Karin Birkenkamp-Demtroder
Journal:  Tumour Biol       Date:  2011-03-12

2.  Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.

Authors:  D J Gottlieb; Y-C Li; I Lionello; S Tanzarella; M Marangolo; K F Bradstock; V Russo; C Traversari
Journal:  Br J Cancer       Date:  2006-07-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.